Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ardelyx Inc (ARDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 285,180
  • Shares Outstanding, K 47,530
  • Annual Sales, $ 0 K
  • Annual Income, $ -112,390 K
  • 36-Month Beta 0.44
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.25

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.50 +5.45%
on 02/09/18
8.10 -28.40%
on 01/23/18
-1.30 (-18.31%)
since 01/16/18
3-Month
5.50 +5.45%
on 02/09/18
8.10 -28.40%
on 01/23/18
+0.20 (+3.57%)
since 11/16/17
52-Week
4.05 +43.21%
on 06/07/17
15.40 -62.34%
on 03/20/17
-7.35 (-55.89%)
since 02/16/17

Most Recent Stories

More News
Ardelyx Announces Departure of Chief Scientific Officer

Ardelyx, Inc. (NASDAQ: ARDX) today announced that Jeremy Caldwell, Ph.D., chief scientific officer, will be leaving the company, effective February 16, 2018, to pursue a position as chief executive officer...

ARDX : 5.80 (-3.33%)
Ardelyx to Participate in Leerink Partners 7th Annual Global Healthcare Conference

Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference at...

ARDX : 5.80 (-3.33%)
Zacks.com highlights: Sanchez Midstream Partners, Tecnoglass, Aeterna Zentaris, Ardelyx and Matrix Service

Zacks.com highlights: Sanchez Midstream Partners, Tecnoglass, Aeterna Zentaris, Ardelyx and Matrix Service

AEZS : 1.90 (-2.56%)
SNMP : 11.70 (-2.90%)
MTRX : 15.50 (unch)
ARDX : 5.80 (-3.33%)
TGLS : 8.96 (+1.36%)
5 Great Breakout Stocks Offering Superlative Returns

This method involved zeroing in on those stocks whose prices are varying within a narrow band.

AEZS : 1.90 (-2.56%)
SNMP : 11.70 (-2.90%)
MTRX : 15.50 (unch)
ARDX : 5.80 (-3.33%)
TGLS : 8.96 (+1.36%)
Stock Review for Biotech's Investors -- Ardelyx, Verastem, and Acceleron Pharma

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on ARDX, VSTM, and XLRN which can be accessed for free by signing up to www.wallstequities.com/registration....

XLRN : 41.97 (-1.18%)
ARDX : 5.80 (-3.33%)
VSTM : 3.31 (+2.64%)
Can The Uptrend Continue for Ardelyx (ARDX)?

Investors certainly have to be happy with Ardelyx Inc (ARDX) and its short term performance

ARDX : 5.80 (-3.33%)
Ardelyx Announces Presentation at J.P. Morgan 36th Annual Healthcare Conference

Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will present a company overview at the J.P. Morgan 36th Annual Healthcare Conference on Wednesday,...

JPM : 114.68 (-0.72%)
ARDX : 5.80 (-3.33%)
Ardelyx Successfully Completes T3MPO-3 Safety Extension Study of Tenapanor for IBS-C

Ardelyx, Inc. (NASDAQ: ARDX) today announced that the company successfully completed the safety extension portion of its Phase 3 T3MPO program, designed to support the registration of tenapanor for the...

ARDX : 5.80 (-3.33%)
Aurora Diagnostics Completed Five Acquisitions, Important Refinancing in 2017

Aurora Diagnostics, the nation's largest independent integrated anatomic pathology and oncology diagnostics practice, is celebrating 2017 achievements that include five acquisitions...

ARDX : 5.80 (-3.33%)
Why Ardelyx (ARDX) Could Beat Earnings Estimates Again

Ardelyx (ARDX) boasts a favorable Zacks Rank and a positive Earnings ESP, which is a great sign of a coming earnings beat.

ARDX : 5.80 (-3.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company's lead product candidate is Tenapanor which is in three ongoing Phase...

See More

Key Turning Points

2nd Resistance Point 6.33
1st Resistance Point 6.07
Last Price 5.80
1st Support Level 5.62
2nd Support Level 5.43

See More

52-Week High 15.40
Fibonacci 61.8% 11.06
Fibonacci 50% 9.73
Fibonacci 38.2% 8.39
Last Price 5.80
52-Week Low 4.05

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.